Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

Market Cap	2.25B +47.0%
Revenue (ttm)	242.10M +165.8%
Net Income	-14.39M
EPS	-0.12
Shares Out	116.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.02 (0.08%)
Ex-Dividend Date	n/a

Volume	1,949,175
Open	19.30
Previous Close	19.30
Day's Range	19.10 - 19.50
52-Week Range	10.00 - 21.40
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About DSE:IBP

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh.

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 127
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: IBP

Financial Performance

In fiscal year 2025, DSE:IBP's revenue was 184.18 million, an increase of 4.27% compared to the previous year's 176.64 million. Losses were -36.83 million, -10.12% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 16, 2026

Data Sources Report a data error